Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06162715CT.gov GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Morbid Obesity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tirzepatide (this asset) | Azienda Sanitaria Locale Napoli 2 Nord | P2/3 | CCC · 55 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Colesevelam | Hvidovre University Hospital | P4 | BBB |
| Chenodeoxycholic Acid | Hvidovre University Hospital | P4 | BBB |
| Ramifentanyl | Hospital dos Lusíadas | P4 | BBB |
| Propofol | G.Gennimatas General Hospital | P4 | BBB |
| Amoxicillin | Fatih Sultan Mehmet Training and Research Hospital | P4 | BBB |
| Semaglutide | Zuyderland Medisch Centrum | P4 | BBB |
| Marcaine | Amany Ahmed Eissa | P4 | BB |
+42 more in the Morbid Obesity cohort
Other indications for Tirzepatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 1 Diabetes Mellitus | — | P4 | BBB · 78 |
| Psoriatic Arthritis | — | P4 | BBB · 74 |
| Diastolic Heart Failure | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tirzepatide in Morbid Obesity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tirzepatide-morbid-obesity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →